Parseghian v. Frequency Therapeutics, Inc.

CourtSuperior Court of Delaware
DecidedMay 18, 2023
DocketN22C-08-153 PRW CCLD
StatusPublished

This text of Parseghian v. Frequency Therapeutics, Inc. (Parseghian v. Frequency Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering Superior Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Parseghian v. Frequency Therapeutics, Inc., (Del. Ct. App. 2023).

Opinion

SUPERIOR COURT OF THE STATE OF DELAWARE

PAUL R. WALLACE LEONARD L. WILLIAMS JUSTICE CENTER JUDGE 500 N. KING STREET, SUITE 10400 WILMINGTON, DELAWARE 19801 (302) 255-0660

Date Submitted: April 28, 2023 Date Decided: May 18, 2023

Kevin R. Shannon, Esquire Deborah S. Birnbach, Esquire Jaclyn C. Levy, Esquire Jennifer Burns Luz, Esquire Callan R. Jackson, Esquire Matthew White, Esquire POTTER ANDERSON & CORROON LLP GOODWIN PROCTER LLP 1313 N. Market Street 100 Northern Avenue Wilmington, Delaware 19801 Boston, Massachusetts 02210

Seth Goldman, Esquire Samuel T. Hirzel, II, Esquire Jacob H. Hupart, Esquire Kelly E. Rowe, Esquire MINTZ, LEVIN, COHN, FERRIS, HEYMAN ENERIO GATTUSO GLOVSKY AND POPEO, P.C. & HIRZEL LLP 919 Third Avenue 300 Delaware Avenue, Suite 200 New York, New York 10022 Wilmington, Delaware 19801

Elena C. Norman, Esquire Adam C. Ford, Esquire Mary F. Dugan, Esquire FORD O’BRIEN LANDY LLP Skyler A. C. Speed, Esquire 275 Madison Avenue, 24th Floor YOUNG CONAWAY STARGATT New York, New York 10016 & TAYLOR, LLP 1000 North King Street Wilmington, Delaware 19801

RE: Gregory J. Parseghian v. Frequency Therapeutics, Inc., et al. C.A. No. N22C-08-153 PRW CCLD Defendants’ Motion to Dismiss

Dear Counsel: This Letter Order resolves Defendants Frequency and Computershare’s Gregory J. Parseghian v. Frequency Therapeutics, Inc., et al. C.A. No. N22C-08-153 PRW CCLD May 18, 2023 Page 2 of 23

Motion to Dismiss the Complaint.1 I. FACTUAL AND PROCEDURAL BACKGROUND Gregory J. Parseghian and Christine M. Parseghian are trustees of two

respective trusts (collectively, the “Trusts”).2 The Trusts hold stock in Frequency

Therapeutics, Inc. (“Frequency”), a biotechnology company.3 The Trusts were early

investors in Frequency before it became a public company.4 When it became a

public company, the Trusts’ Series A preferred stock was transferred to common

stock.5

Frequency selected Computershare, Inc.’s wholly-owned subsidiary

Computershare Trust Company, N.A. (“Computershare”) to serve as “Frequency’s

corporate transfer agent and provide a suite of investor services.”6 One of

Computershare’s duties as transfer agent was “to register transfers of securities.”7

The “records and accounts of [the Trusts’] shares [in Frequency] were maintained

1 Computershare and Frequency both moved to dismiss the complaint and submitted a joint opening brief in support of their motions. D.I. 12, D.I. 13. 2 Compl. at 1 (D.I. 1). 3 Id. ¶ 1. 4 Id. ¶ 22. 5 Id. ¶¶ 28-29. 6 Id. ¶¶ 1, 9, 31. 7 Id. ¶ 31. Gregory J. Parseghian v. Frequency Therapeutics, Inc., et al. C.A. No. N22C-08-153 PRW CCLD May 18, 2023 Page 3 of 23

by Computershare.”8

Due to a rise in the stock price, the Trusts decided to sell their shares in

Frequency.9 To affect this sale, on February 2, 2021, the Trusts contacted

Computershare and instructed it to “transfer the [Trusts’] Frequency shares to their

respective accounts at J.P. Morgan.”10

The Trusts allege that over the next seven weeks Computershare hindered the

Trusts’ attempt to transfer their shares thus prohibiting them from reaching J.P.

Morgan, the broker that was needed to effectuate the sale. The Trusts assert that

Computershare informed them that the account names at J.P. Morgan did not match

the account names at Computershare.11 The Trusts say they fixed the issues (which

they insist were caused by Computershare’s own notation errors) but that

Computershare continued to decline to approve the transfer requests.12

After seven weeks of attempts—and on the day Frequency’s stock price

8 Id. ¶ 60. 9 Id. ¶¶ 57-61. 10 Id. ¶ 61. 11 Id. ¶¶ 65, 77-78. In addition to the names not matching exactly, the Trusts assert that Computershare claimed a ‘transfer of death’ notation on the Trusts’ Computershare accounts “made it possible that J.P. Morgan was attempting to transfer shares to an account held for different people” and so it prohibited the transfer. Id. ¶¶ 77-78. 12 Id. ¶¶ 79-81. Gregory J. Parseghian v. Frequency Therapeutics, Inc., et al. C.A. No. N22C-08-153 PRW CCLD May 18, 2023 Page 4 of 23

plummeted (March 24, 2021)—the Trusts say Computershare finally approved the

transfer. 13

According to the Trusts, Computershare’s actions were the result of a

coordinated campaign between Frequency and Computershare to prohibit or delay

Frequency stockholders from transferring their shares to brokerages so as to prohibit

increased sales activity.14 This, it says: (1) allowed the stock price to artificially

increase; and (2) allowed Frequency executives to sell their stock at those artificially

higher prices.15 In support, the Trusts point to Frequency’s CEO selling over

350,000 shares of Frequency stock between February 1, 2021 and March 1, 2021.16

In the Complaint, the Trusts pen four claims: breach of the statutory duty of

care against Frequency and Computershare, jointly and severally (Count I);

negligence against Frequency and Computershare, jointly and severally (Count II);

13 Id. ¶¶ 80-81. 14 Id. ¶¶ 89-91. 15 Id. ¶¶ 89-91, 95 (“The only other plausible explanation, alleged here in the alternative, is that Frequency, with the goal of causing delay, communicated and/or refused to cooperate with Computershare in order to procure the delay of the transfer of the Plaintiffs’ shares to J.P. Morgan and prevent their subsequent sale until after Frequency announced the negative news regarding its Phase 2a study. Frequency and its management knew that announcement spelled the end of its share value. As a result of their actions and omissions, the Defendants converted the Plaintiffs’ shares and unjustly enriched Frequency.”); id. ¶ 89 (asserting Frequency wanted to give “management time to profit by selling their shares of the company, while other shareholders could not”). 16 Id. ¶ 91. Gregory J. Parseghian v. Frequency Therapeutics, Inc., et al. C.A. No. N22C-08-153 PRW CCLD May 18, 2023 Page 5 of 23

conversion against Frequency and Computershare, jointly and severally (in the

alternative to Counts I and II) (Count III); unjust enrichment against Frequency and

Computershare, jointly and severally (in the alternative to Counts I and II) (Count

IV).17

Defendants have moved to dismiss the Complaint under Superior Court Civil

Rules 12(b)(6) and 9(b).

II. STANDARD OF REVIEW “Under Superior Court Civil Rule 12(b)(6), ‘[t]he legal issue to be decided is,

whether a plaintiff may recover under any reasonably conceivable set of

circumstances susceptible of proof under the complaint.’”18 Under that Rule, the

Court will

(1) accept all well pleaded factual allegations as true, (2) accept even vague allegations as “well pleaded” if they give the opposing party notice of the claim, (3) draw all reasonable inferences in favor of the non-moving party, and (4) [not dismiss the claims] unless the plaintiff would not be entitled to recover under any reasonably conceivable set of circumstances.19

“If any reasonable conception can be formulated to allow Plaintiffs’ recovery,

17 Id. ¶¶ 96-163. 18 Vinton v. Grayson, 189 A.3d 695, 700 (Del. Super. Ct. 2018) (alteration in original) (quoting Super. Ct. Civ. R. 12(b)(6)). 19 Id. (alteration in original) (quoting Cent. Mortg. Co. v. Morgan Stanley Mortg. Cap. Hldgs. LLC, 27 A.3d 531, 535 (Del. 2011)). Gregory J. Parseghian v. Frequency Therapeutics, Inc., et al. C.A. No. N22C-08-153 PRW CCLD May 18, 2023 Page 6 of 23

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Stinger v. Chase Bank, USA, NA
265 F. App'x 224 (Fifth Circuit, 2008)
Ryan v. Gifford
918 A.2d 341 (Court of Chancery of Delaware, 2007)
In Re HealthSouth Corp. Shareholders Litigation
845 A.2d 1096 (Court of Chancery of Delaware, 2003)
Danforth v. Acorn Structures, Inc.
608 A.2d 1194 (Supreme Court of Delaware, 1992)
Myer v. Dyer
542 A.2d 802 (Superior Court of Delaware, 1987)
Arnold v. Society for Sayings Bancorp, Inc.
678 A.2d 533 (Supreme Court of Delaware, 1996)
Fisher v. Townsends, Inc.
695 A.2d 53 (Supreme Court of Delaware, 1997)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
Kuroda v. SPJS Holdings, L.L.C.
971 A.2d 872 (Court of Chancery of Delaware, 2009)
Celanese Corp. of America v. Mayor of Wilmington
78 A.2d 249 (Superior Court of Delaware, 1950)
VLIW TECHNOLOGY, LLC v. Hewlett-Packard Co.
840 A.2d 606 (Supreme Court of Delaware, 2003)
Weiss v. Swanson
948 A.2d 433 (Court of Chancery of Delaware, 2008)
Fleer Corp. v. Topps Chewing Gum, Inc.
539 A.2d 1060 (Supreme Court of Delaware, 1988)
Hudson v. Old Guard Insurance Co.
3 A.3d 246 (Supreme Court of Delaware, 2010)
Vinton v. Grayson
189 A.3d 695 (Superior Court of Delaware, 2018)
COR Clearing, LLC v. Calissio Resources Group, Inc.
918 F.3d 579 (Eighth Circuit, 2019)
Drug, Inc. v. Hunt
168 A. 87 (Supreme Court of Delaware, 1933)
In re Galena Biopharma, Inc.
83 F. Supp. 3d 1047 (D. Oregon, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Parseghian v. Frequency Therapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/parseghian-v-frequency-therapeutics-inc-delsuperct-2023.